Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
74.05
-0.27 (-0.36%)
At close: May 22, 2026, 4:00 PM EDT
74.05
0.00 (0.00%)
After-hours: May 22, 2026, 4:10 PM EDT

Spyre Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
6,4313,0371,40377629234
Market Cap Growth
752.86%116.48%80.78%2538.59%-87.46%-37.89%
Enterprise Value
5,7242,436955.52706.15-22.3145.92
Last Close Price
74.0532.7623.2821.5211.25118.75
PB Ratio
11.384.252.714.220.582.79
P/TBV Ratio
9.522.932.110.810.753.72
EV/EBITDA Ratio
----0.27-
EV/EBIT Ratio
----0.26-
EV/FCF Ratio
----0.28-
Debt / Equity Ratio
-0000.080.05
Net Debt / Equity Ratio
-1.10-1.06-1.16-1.84-1.01-1.05
Net Debt / EBITDA Ratio
3.683.612.891.410.611.38
Net Debt / FCF Ratio
3.994.473.833.400.641.62
Quick Ratio
8.7112.8911.1610.613.834.66
Current Ratio
8.9713.2511.2610.684.254.91
Return on Equity (ROE)
-25.89%-25.17%-59.28%-289.17%-124.87%-58.81%
Return on Assets (ROA)
-26.16%-30.24%-43.88%-117.35%-93.80%-48.25%
Return on Invested Capital (ROIC)
1495.32%1115.27%1212.19%5099.90%-12415.00%9850.83%
Return on Capital Employed (ROCE)
-28.85%-32.91%-48.26%-132.27%-115.92%-55.88%
Buyback Yield / Dilution
-29.57%-36.21%-581.85%-104.57%-28.20%-23.19%
Total Shareholder Return
-29.57%-36.21%-581.85%-104.57%-28.20%-23.19%
Updated May 5, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q